TWO DOSES OF GW433908/RITONAVIR GIVEN WITH ABACAVIR/LAMIVUDINE COMBO

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是：1）确定服用福沙那韦100 mg RTV + ABC/3 TC FDC是否与服用福沙那韦200 mg RTV + ABC/3 TC FDC一样有效; 2）测量T细胞; 3）收集两种治疗的安全性信息; 4）评估脂肪代谢障碍综合征的体征和症状; 5）在某些时间点测量血液中安普那韦的量，以确定是否正确服用药物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purposes of this study are: 1) to find out if taking fosamprenavir with 100 mg RTV plus ABC/3TC FDC is as effective as taking fosamprenavir with 200 mg RTV plus ABC/3TC FDC; 2) to measure T-cells; 3) to collect information on the safety of the two treatments; 4) to assess the physical signs and symptoms of lipodystrophy syndrome; 5) to measure the amounts of amprenavir in blood at certain time points to find out if medication has been taken correctly.